Par Pharmaceutical Cos., Inc. (PRX) Tops Q3 EPS by 1c, Sales Miss Expectations
Tweet
Share
E-mailGet Alerts PRX Hot Sheet
Price: $49.98 --0%
Financial Fact:
Interest expense: -39.99M
Today's EPS Names:
OTLK, EGRX, MOVE, More
Financial Fact:
Interest expense: -39.99M
Today's EPS Names:
OTLK, EGRX, MOVE, More
Join SI Premium – FREE
Par Pharmaceutical Cos., Inc. (NYSE: PRX) reported Q3 non-GAAP EPS of $0.74, $0.01 better than the analyst estimate of $0.73. Revenue for the quarter came in at $215.4 million versus the consensus estimate of $309.97 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- Tenon Medical (TNON) Misses Q2 EPS by 395c
- Prosensa Holding N.V. (RNA) Reports Q2 Loss of $1.18
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
